Osteomalacia
13
1
1
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.7%
1 terminated out of 13 trials
90.0%
+3.5% vs benchmark
8%
1 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (13)
A Natural History Study of Bone and Mineral Disorders
Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia
Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced Osteomalacia
Serum Prolidase Activity and the Role of Leptin in Osteomalacia
Studies of States With Resistance to Vitamin D and Parathyroid Hormone
Dental Implants Rehabilitation in Patients With Vitamin D3 Imbalance
Study of the Diagnostic Value of Stable Calcium Isotope Profiling in Bone and Calcium Disorders
COMPREHENSIVE® REVERSE SHOULDER Mini BasePlate
Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)
Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia
Maternal and Infant Vitamin Status During the First Nine Months of Infant Life
Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density
Serum FGF-23 and Vitamin D Deficiency